Raymond James & Associates Humacyte, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Humacyte, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 43,278 shares of HUMA stock, worth $102,136. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,278Holding current value
$102,136% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding HUMA
# of Institutions
181Shares Held
59.9MCall Options Held
1.05MPut Options Held
877K-
Black Rock Inc. New York, NY7.14MShares$16.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.6MShares$15.6 Million0.0% of portfolio
-
State Street Corp Boston, MA4.27MShares$10.1 Million0.0% of portfolio
-
Heights Capital Management, Inc San Francisco, CA4.03MShares$9.5 Million3.22% of portfolio
-
Woodline Partners LP San Francisco, CA3.95MShares$9.32 Million0.05% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $243M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...